Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
Orion Research Foundation sr is distributing EUR 1,004,800 in research grants based on applications for 2019.
Orion aims to build well-being in ALS by developing effective new treatments to help patients manage their illness and improve their quality of life.
Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs.
Like in all other operations, our aim is to work in accordance with the requirements, standards and ethical codes of our industry in our pharmaceutical research and development activities too. Our R&D Policy highlights how we make sure that our practices are on an ethically sustainable basis.
Partnerships and networking are important for Orion throughout the entire value chain of operations. We collaborate with other companies in research and development, manufacturing and marketing of products internationally.
